CLAIMS

1. Trivalent polypeptide that is directed against protein F of hRSV, which is chosen from any one of (A) to (C):

   (A) trivalent polypeptide chosen from the following polypeptides:

   a) SEQ ID NO's: 142-145 and 162-165;

   b) SEQ ID NO's: 77-79 and 158;

   c) SEQ ID NO's: 159-161;

   (B) trivalent polypeptide comprising or consisting of three amino acid sequences ~~and/or Nanobodies®~~ that each comprise at least

   ~~a first stretch of amino acid residues chosen:~~

   a) SEQ ID NO: 98;

   ~~and a second stretch of amino acid residues chosen from:~~

   b) SEQ ID NO: 102; and

   ~~and a third stretch of amino acid residues chosen from:~~

   c) SEQ ID NO: 121;

   (C) trivalent polypeptide comprising or consisting of three amino acid sequence~~Nanobodies®~~, ~~wherein Nanobody is~~ chosen from the following a) to b):

   a) SEQ ID NO's: 60-76;

   b) SEQ ID NO's: 146-153;

2. Trivalent polypeptide comprising or consisting of SEQ ID NO: 53,

   - wherein the first Glutamic acid has been changed into Aspartic acid.

~~3. Trivalent polypeptide comprising or consisting of SEQ ID NO: 53, in which in at least one Nanobody® that forms part of SEQ ID NO: 53, following amino acid residue(s) have been mutated:~~

~~— Val5Leu, Ala14Pro, Glu44Gly, Gly78Leu, Ala83Arg, Asp85Glu, Arg105Gln and Gln108Leu;~~

~~— Ala83Arg, Asp85Glu, Arg105Gln and Gln108Leu;~~

~~— Gly78Leu, Ala83Arg, Asp85Glu and Arg105Gln;~~

~~— Val5Leu, Ala14Pro, Glu44Gly, Gly78Leu, Ala83Arg, Asp85Glu, Arg105Gln, Gln108Leu and Gly54Asp;~~

~~— Ala83Arg, Asp85Glu, Arg105Gln, Gln108Leu and Gly54Asp;~~

~~Gly78Leu, Ala83Arg, Asp85Glu, Arg105Gln and Gly54Asp;~~

~~Gly54Asp;~~

~~Ala14Pro, Ser19Arg, Ile20Leu and Gln108Leu;~~

~~Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu and Ala83Arg;~~

~~Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu and Asp85Glu;~~

~~Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu and Arg105Gln;~~

~~Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Ala83Arg and Asp85Glu;~~

~~Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Ala83Arg and Arg105Gln;~~

~~Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Asp85Glu and Arg105Gln;~~

~~Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Ala83Arg, Asp85Glu and Arg105Gln.~~

~~Glu1Asp;~~

~~Glu1Asp, Val5Leu, Ala14Pro, Glu44Gly, Gly78Leu, Ala83Arg, Asp85Glu, Arg105Gln and Gln108Leu;~~

~~Glu1Asp, Ala83Arg, Asp85Glu, Arg105Gln and Gln108Leu;~~

~~Glu1Asp, Gly78Leu, Ala83Arg, Asp85Glu and Arg105Gln;~~

~~Glu1Asp, Val5Leu, Ala14Pro, Glu44Gly, Gly78Leu, Ala83Arg, Asp85Glu, Arg105Gln, Gln108Leu and Gly54Asp;~~

~~Glu1Asp, Ala83Arg, Asp85Glu, Arg105Gln, Gln108Leu and Gly54Asp;~~

~~Glu1Asp, Gly78Leu, Ala83Arg, Asp85Glu, Arg105Gln and Gly54Asp;~~

~~Glu1Asp and Gly54Asp;~~

~~Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu and Gln108Leu;~~

~~Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu and Ala83Arg;~~

~~Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu and Asp85Glu ;~~

~~Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu and Arg105Gln;~~

~~Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Ala83Arg and Asp85Glu;~~

~~Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Ala83Arg and Arg105Gln;~~

~~Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Asp85Glu and Arg105Gln; or~~

~~Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Ala83Arg, Asp85Glu and Arg105Gln.~~

43. Trivalent polypeptide according to any of claims 1 to 2~~3~~, comprising or consisting of one of SEQ ID NO's: 77-79, 142-145 and 158-165.

45. Method for preparing a trivalent polypeptide according to any of claims 1 to 34, said method comprising at least the steps of linking three monovalent amino acid sequences or monovalent construct selected from:

a) SEQ ID NO's: 60-76;

b) SEQ ID NO's: 146-153;

c) SEQ ID NO's: 138-141 and 154-157;

and, optionally, for example one or more linkers.

56. Monovalent construct, comprising or consisting of one amino acid sequence Nanobody® as described in claim 45.

67. Nucleic acid or nucleotide sequence, that encodes a polypeptide according to any of claims 1 to 34, or a monovalent construct according to claim 56.

78. Use of a nucleic acid or nucleotide sequence according to claim 67, that encodes a monovalent construct according to claim 56, for the preparation of a genetic construct that encodes a multivalent polypeptide according to any of claims 1 to 34.

89. Host or host cell that expresses a polypeptide according to any of claims 1 to 34, or a monovalent construct according to claim 56; and/or that comprises a nucleic acid or nucleotide sequence according to claim 67.

910. Composition comprising a polypeptide according to any of claims 1 to 34, or a monovalent construct according to claim 56, or nucleic acid or nucleotide sequence according to claim 67.

1011. Composition according to claim 910, which is a pharmaceutical composition.

1112. Pharmaceutical composition comprising a polypeptide according to any of claims 1 to 34, or a monovalent construct according to claim 56, and a carrier suitable for pulmonary delivery.

1213. Method for producing a polypeptide according to any of claims 1 to 34, or a monovalent construct according to claim 56, or a composition according to any of claims 910 or 1011, said method at least comprising the steps of:

a) expressing, in a suitable host cell or host organism or in another suitable expression system, a nucleic acid or nucleotide sequence according to claim 6~~7~~,
or cultivating and/or maintaining a host or host cell according to claim 8~~9~~ under conditions that are such that said host or host cell expresses and/or produces a polypeptide according to any of claims 1 to 3~~4~~, or a monovalent construct according to claim 5~~6~~, or composition according to any of claims 9~~10~~ or 10~~11~~, optionally followed by:

b) isolating and/or purifying the polypeptide according to any of claims 1 to 3~~4~~, or the monovalent construct according to claim 5~~6~~, thus obtained.

13~~14~~. A polypeptide according to any of claims 1 to 3~~4~~, or a monovalent construct according to claim 5~~6~~ and/or composition according to any of claims 9~~10~~ or 10~~11~~ for prevention and/or treatment of at least one of respiratory illness, upper respiratory tract infection, lower respiratory tract infection, bronchiolitis (inflammation of the small airways in the lung), pneumonia, dyspnea, cough, (recurrent) wheezing and asthma.

14~~15~~. Pharmaceutical device suitable for the pulmonary delivery comprising a polypeptide according to any of claims 1 to 3~~4~~, or a monovalent construct according to claim 5~~6~~ and/or a composition comprising the same.

15~~16~~. Pharmaceutical device according to claim 14~~15~~ that is an inhaler for liquids (e.g. a suspension of fine solid particles or droplets), an aerosol or a dry powder inhaler, comprising a polypeptide according to any of claims 1 to 3~~4~~, or a monovalent construct according to claim 5~~6~~.